Overview

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Antibodies, Monoclonal
Docetaxel
Hormones
Prednisone